Utilization of lymph node assessment in patients with ductal carcinoma in situ treated with lumpectomy

Dhruvil R. Shah, Robert J Canter, Vijay P. Khatri, Richard J Bold, Steve R. Martinez

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Background: Lymph node assessment (LNA), including sentinel lymph node biopsy (SLNB), is controversial in patients undergoing lumpectomy for ductal carcinoma in situ (DCIS). Our goal was to identify factors influencing LNA in these patients. Methods: We used the Surveillance Epidemiology and End Results database to identify all female patients treated with lumpectomy for DCIS from 2000 to 2008. We excluded patients without histologic confirmation, including those diagnosed at autopsy, and those for whom LNA status was unknown. Multivariate logistic regression models predicted use of LNA. Likelihood of undergoing LNA was reported as odds ratios (ORs) with 95% confidence intervals (CIs). Results: A total of 62,935 patients met inclusion criteria. Approximately 15% (N = 9726) had regional LNA at the time of lumpectomy, with 12% (N = 7294) undergoing SLNB. Factors associated with an increased likelihood of undergoing LNA included treatment in the Southeast (OR 1.25, CI 1.04-1.22); treatment after the year 2000; grade II (OR 2.71, CI 2.48-2.96), III (OR 2.38, CI 2.18-2.59), or IV (OR 2.61, CI 2.37-2.88) tumors; DCIS size 2-5 cm (OR 1.49, CI 1.37-1.62) or >5 cm (OR 2.16, CI 1.78-2.61), and estrogen receptor-negative (OR 1.29, CI 1.16-1.43) or progesterone receptor-negative (OR 1.22, CI 1.11-1.33) tumors. Factors associated with a decreased likelihood of undergoing regional LNA were age >60 (OR 0.83, CI 0.79-0.87), and Asian race (OR 0.88, CI 0.81-0.96). Factors predictive of LNA in general were also predictive of SLNB. Conclusions: Although LNA is controversial for patients undergoing lumpectomy for DCIS, it is used in 15% of cases. Further research establishing for the benefit of LNA in DCIS patients treated with lumpectomy is needed.

Original languageEnglish (US)
JournalJournal of Surgical Research
Volume177
Issue number1
DOIs
StatePublished - Sep 2012

Fingerprint

Carcinoma, Intraductal, Noninfiltrating
Segmental Mastectomy
Lymph Nodes
Odds Ratio
Confidence Intervals
Sentinel Lymph Node Biopsy
Logistic Models
Progesterone Receptors
Estrogen Receptors
Autopsy
Neoplasms
Epidemiology
Databases

Keywords

  • Ductal carcinoma in situ
  • Lumpectomy
  • Lymph node assessment
  • SEER
  • Sentinel lymph node biopsy

ASJC Scopus subject areas

  • Surgery

Cite this

Utilization of lymph node assessment in patients with ductal carcinoma in situ treated with lumpectomy. / Shah, Dhruvil R.; Canter, Robert J; Khatri, Vijay P.; Bold, Richard J; Martinez, Steve R.

In: Journal of Surgical Research, Vol. 177, No. 1, 09.2012.

Research output: Contribution to journalArticle

@article{b5a63e31d0f04c5a9201e9cf65432e87,
title = "Utilization of lymph node assessment in patients with ductal carcinoma in situ treated with lumpectomy",
abstract = "Background: Lymph node assessment (LNA), including sentinel lymph node biopsy (SLNB), is controversial in patients undergoing lumpectomy for ductal carcinoma in situ (DCIS). Our goal was to identify factors influencing LNA in these patients. Methods: We used the Surveillance Epidemiology and End Results database to identify all female patients treated with lumpectomy for DCIS from 2000 to 2008. We excluded patients without histologic confirmation, including those diagnosed at autopsy, and those for whom LNA status was unknown. Multivariate logistic regression models predicted use of LNA. Likelihood of undergoing LNA was reported as odds ratios (ORs) with 95{\%} confidence intervals (CIs). Results: A total of 62,935 patients met inclusion criteria. Approximately 15{\%} (N = 9726) had regional LNA at the time of lumpectomy, with 12{\%} (N = 7294) undergoing SLNB. Factors associated with an increased likelihood of undergoing LNA included treatment in the Southeast (OR 1.25, CI 1.04-1.22); treatment after the year 2000; grade II (OR 2.71, CI 2.48-2.96), III (OR 2.38, CI 2.18-2.59), or IV (OR 2.61, CI 2.37-2.88) tumors; DCIS size 2-5 cm (OR 1.49, CI 1.37-1.62) or >5 cm (OR 2.16, CI 1.78-2.61), and estrogen receptor-negative (OR 1.29, CI 1.16-1.43) or progesterone receptor-negative (OR 1.22, CI 1.11-1.33) tumors. Factors associated with a decreased likelihood of undergoing regional LNA were age >60 (OR 0.83, CI 0.79-0.87), and Asian race (OR 0.88, CI 0.81-0.96). Factors predictive of LNA in general were also predictive of SLNB. Conclusions: Although LNA is controversial for patients undergoing lumpectomy for DCIS, it is used in 15{\%} of cases. Further research establishing for the benefit of LNA in DCIS patients treated with lumpectomy is needed.",
keywords = "Ductal carcinoma in situ, Lumpectomy, Lymph node assessment, SEER, Sentinel lymph node biopsy",
author = "Shah, {Dhruvil R.} and Canter, {Robert J} and Khatri, {Vijay P.} and Bold, {Richard J} and Martinez, {Steve R.}",
year = "2012",
month = "9",
doi = "10.1016/j.jss.2012.03.015",
language = "English (US)",
volume = "177",
journal = "Journal of Surgical Research",
issn = "0022-4804",
publisher = "Academic Press Inc.",
number = "1",

}

TY - JOUR

T1 - Utilization of lymph node assessment in patients with ductal carcinoma in situ treated with lumpectomy

AU - Shah, Dhruvil R.

AU - Canter, Robert J

AU - Khatri, Vijay P.

AU - Bold, Richard J

AU - Martinez, Steve R.

PY - 2012/9

Y1 - 2012/9

N2 - Background: Lymph node assessment (LNA), including sentinel lymph node biopsy (SLNB), is controversial in patients undergoing lumpectomy for ductal carcinoma in situ (DCIS). Our goal was to identify factors influencing LNA in these patients. Methods: We used the Surveillance Epidemiology and End Results database to identify all female patients treated with lumpectomy for DCIS from 2000 to 2008. We excluded patients without histologic confirmation, including those diagnosed at autopsy, and those for whom LNA status was unknown. Multivariate logistic regression models predicted use of LNA. Likelihood of undergoing LNA was reported as odds ratios (ORs) with 95% confidence intervals (CIs). Results: A total of 62,935 patients met inclusion criteria. Approximately 15% (N = 9726) had regional LNA at the time of lumpectomy, with 12% (N = 7294) undergoing SLNB. Factors associated with an increased likelihood of undergoing LNA included treatment in the Southeast (OR 1.25, CI 1.04-1.22); treatment after the year 2000; grade II (OR 2.71, CI 2.48-2.96), III (OR 2.38, CI 2.18-2.59), or IV (OR 2.61, CI 2.37-2.88) tumors; DCIS size 2-5 cm (OR 1.49, CI 1.37-1.62) or >5 cm (OR 2.16, CI 1.78-2.61), and estrogen receptor-negative (OR 1.29, CI 1.16-1.43) or progesterone receptor-negative (OR 1.22, CI 1.11-1.33) tumors. Factors associated with a decreased likelihood of undergoing regional LNA were age >60 (OR 0.83, CI 0.79-0.87), and Asian race (OR 0.88, CI 0.81-0.96). Factors predictive of LNA in general were also predictive of SLNB. Conclusions: Although LNA is controversial for patients undergoing lumpectomy for DCIS, it is used in 15% of cases. Further research establishing for the benefit of LNA in DCIS patients treated with lumpectomy is needed.

AB - Background: Lymph node assessment (LNA), including sentinel lymph node biopsy (SLNB), is controversial in patients undergoing lumpectomy for ductal carcinoma in situ (DCIS). Our goal was to identify factors influencing LNA in these patients. Methods: We used the Surveillance Epidemiology and End Results database to identify all female patients treated with lumpectomy for DCIS from 2000 to 2008. We excluded patients without histologic confirmation, including those diagnosed at autopsy, and those for whom LNA status was unknown. Multivariate logistic regression models predicted use of LNA. Likelihood of undergoing LNA was reported as odds ratios (ORs) with 95% confidence intervals (CIs). Results: A total of 62,935 patients met inclusion criteria. Approximately 15% (N = 9726) had regional LNA at the time of lumpectomy, with 12% (N = 7294) undergoing SLNB. Factors associated with an increased likelihood of undergoing LNA included treatment in the Southeast (OR 1.25, CI 1.04-1.22); treatment after the year 2000; grade II (OR 2.71, CI 2.48-2.96), III (OR 2.38, CI 2.18-2.59), or IV (OR 2.61, CI 2.37-2.88) tumors; DCIS size 2-5 cm (OR 1.49, CI 1.37-1.62) or >5 cm (OR 2.16, CI 1.78-2.61), and estrogen receptor-negative (OR 1.29, CI 1.16-1.43) or progesterone receptor-negative (OR 1.22, CI 1.11-1.33) tumors. Factors associated with a decreased likelihood of undergoing regional LNA were age >60 (OR 0.83, CI 0.79-0.87), and Asian race (OR 0.88, CI 0.81-0.96). Factors predictive of LNA in general were also predictive of SLNB. Conclusions: Although LNA is controversial for patients undergoing lumpectomy for DCIS, it is used in 15% of cases. Further research establishing for the benefit of LNA in DCIS patients treated with lumpectomy is needed.

KW - Ductal carcinoma in situ

KW - Lumpectomy

KW - Lymph node assessment

KW - SEER

KW - Sentinel lymph node biopsy

UR - http://www.scopus.com/inward/record.url?scp=84865074631&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84865074631&partnerID=8YFLogxK

U2 - 10.1016/j.jss.2012.03.015

DO - 10.1016/j.jss.2012.03.015

M3 - Article

VL - 177

JO - Journal of Surgical Research

JF - Journal of Surgical Research

SN - 0022-4804

IS - 1

ER -